Takeda Pharmaceuticals NorthAmerica, Inc., today announced the incorporation of Takeda PharmaceuticalsMexico, S.A. de C.V. This expansion strengthens the company's North Americanpresence, bolstering existing operations in the United States and Canada.Takeda Pharmaceuticals Mexico will be headquartered in Mexico City.The Mexican pharmaceutical market is currently the 12th largest in theworld and represents more than 25 percent of the Latin American market.Additionally, the prevalence of diabetes in Mexico is among the highest in theworld. "With a population of 109 million people, Mexico represents an importantexpansion opportunity for Takeda," said Shinji Honda, President and ChiefExecutive Officer, Takeda Pharmaceuticals North America, Inc. "The needs ofpatients in Mexico fit well with our product portfolio, so we are excited tobring important medicines to this vital region." Takeda Mexico plans to file a new drug application with the FederalCommission for the Protection against Sanitary Risk (COFEPRIS) in 2010. Takedafocuses on a variety of therapeutic areas, including lifestyle-relateddiseases, oncology and urological diseases, central nervous system diseases,and gastroenterological diseases. "For us, it is a pleasure that Takeda has chosen Mexico to startoperations," said Bruno Ferrari, Chief Executive Officer of ProMexico,Mexico's Federal Government entity responsible for bringing direct foreigninvestment into Mexico as well as to support the country's foreign trade."Takeda's experience is of great importance not only because of the company'scontributions to Mexico's health system, but also the jobs that will bebrought to Mexico's qualified labor force."